Editorial policy, sourcing, and who publishes this
Stem Cell Seoul is published and funded by Delight Dermatology Clinic in Seocho-gu, Seoul. It provides educational information about regenerative medicine and does not offer or price treatments.
Who publishes this
hifuseoul.com · Clinician credentials
Content is written by the Stem Cell Seoul editorial team and reviewed by a Korean Board-Certified Dermatologist who is an AAD International Fellow and an ASLMS member.
Regulatory scope
FDA status is checked for the named stem-cell or exosome product and its indication. An approval for one disease does not establish approval for aesthetic use or authorisation to provide it in Korea.
Ryoncil (remestemcel-L-rknd) is an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older. FDA product record. This disease-specific approval does not establish aesthetic approval, Korean authorisation, or provision by the publisher.
Source selection
Retrieved from the database
Sources are pulled from PubMed and pasted, never reconstructed from memory.
Retractions excluded
One otherwise relevant review is deliberately absent, and the exclusion is recorded in the source file.
Study design stated
The sentence carries the design that supports it: a finding in cell culture is described as one.
Authors' own limits carried
If reviewers graded their evidence low certainty, that grade appears in our sentence too.
Checked before every build
Prices, offer claims, held routes and unnegated approval claims fail the build rather than warn.
Clinical statements rest on nineteen peer-reviewed references, each retrieved from PubMed and recorded with its PMID and DOI so a reader can check it. Preference goes to systematic reviews and meta-analyses, then to randomised trials, then to narrative reviews, and mechanism-only studies are labelled as such in the text rather than presented as clinical evidence.
Bibliographic details are checked against PubMed records. Retracted studies are excluded.
Primary regulatory sources
Regulatory statements rest on primary documents rather than on secondary reporting. Each is published with its scope limit attached, because both documents are frequently cited to support conclusions they do not reach.
How claims are framed
Three framing rules apply throughout. Effect claims carry the study design that supports them and the limit the authors themselves stated: if reviewers graded their evidence low certainty, that grade appears in our sentence too. Mechanism is never presented as outcome; a finding in fibroblast culture is described as a finding in fibroblast culture. And regulatory status in one jurisdiction is never offered as evidence about another, in either direction.
Review and revision
Medical review dates and editorial updates are shown separately on each page where applicable.
Pages are revised when the underlying evidence changes, when a cited source is retracted or superseded, when regulation is amended, or when an error is reported and confirmed.
Corrections
If you believe something here is wrong, tell us and cite the source that shows it. Corrections to matters of fact are made and the page’s revision date updated. Contact runs through the publisher’s clinic site at hifuseoul.com.
Funding and advertising
The site is funded entirely by the publisher. It carries no advertising, no affiliate links, no sponsored content, and no commercial relationship with any manufacturer of any product described. Nothing on the site is paid placement.
Written by the Stem Cell Seoul editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-08-30. Editorially updated 2026-09-29.